

COMIRNATY® JN.1 COVID-19 vaccine

Active ingredient: bretovameran

Consumer Medicine Information

This leaflet provides important information about using COMIRNATY JN.1. **You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about receiving COMIRNATY JN.1.**

produce antibodies and blood cells that work against the virus, to protect against COVID-19 disease.

Where to find information in this leaflet:

1. Why am I being given COMIRNATY JN.1?
2. What should I know before I am given COMIRNATY JN.1?
3. What if I am taking other medicines?
4. How will I be given COMIRNATY JN.1?
5. What should I know while being given COMIRNATY JN.1?
6. Are there any side effects?
7. Product details

1. Why am I being given COMIRNATY JN.1?

COMIRNATY JN.1 contains the active ingredient bretovameran.

COMIRNATY JN.1 is an mRNA (messenger ribonucleic acid) vaccine.

COMIRNATY JN.1 is a vaccine given to prevent COVID-19 disease caused by SARS-CoV-2 virus in adults, infants and children from 6 months of age and older.

COMIRNATY JN.1 works by triggering your immune system to